A study presented at ESCMID Global 2026 reports that antiretroviral therapy can reduce HIV-associated biological aging by nearly four years, based on blood protein patterns.
The research team developed a plasma proteomic aging clock, a model that estimates biological age by measuring hundreds of proteins in blood. The model was trained using samples from people with HIV who were successfully receiving antiretroviral therapy and then tested in a separate group with samples collected before and after treatment.
Before treatment, when HIV was detectable in blood, participants showed a median biological age acceleration of 10 years. After a median of 1.55 years of antiretroviral therapy, the researchers measured an average reduction of 3.7 years in proteomic age. Longer time on therapy was linked with continued movement toward chronological age.
The study suggests the effect is broader than T-cell count recovery alone. The aging clock appeared sensitive to short-term immune and inflammatory changes, and the reversal of age acceleration was not tightly tied to CD4 or CD8 T-cell recovery. That points to wider immune remodeling once HIV is suppressed.
More validation is needed in diverse populations, and the authors called for additional work to identify the exact pathways driving HIV-related aging biology. For patients and clinicians, the message still aligns with current standards: early diagnosis, prompt treatment, and sustained viral suppression are central to long-term health.